Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis.

Abstract

OBJECTIVE:

Systemic sclerosis-associated pulmonary arterial hypertension differs from idiopathic pulmonary arterial hypertension with respect to histopathology, treatment responses and survival. Medical progress on PAH is hampered by the lack of human biosamples and suitable animal models. In this study, the authors evaluated fos-related antigen 2 (Fra-2) transgenic mice as a novel model for systemic sclerosis-associated pulmonary arterial hypertension.

METHODS:

Lung sections of Fra-2 transgenic (n=12) and wild-type mice (n=6) were analysed at 16 weeks by histology using Dana Point criteria. Cellular and molecular key players were assessed by immunohistochemistry. To test the model's sensitivity to change over treatment, a subgroup of Fra-2 transgenic mice (n=6) was treated with the tyrosine kinase inhibitor nilotinib twice daily 37.5 mg orally from 8 weeks of age.

RESULTS:

Fra-2 transgenic mice developed severe vascular remodelling of pulmonary arteries and non-specific interstitial pneumonia-like interstitial lung disease resembling human systemic sclerosis-associated pulmonary hypertension. Histological features typical for systemic sclerosis-associated pulmonary arterial hypertension, such as intimal thickening with concentric laminar lesions, medial hypertrophy, perivascular inflammatory infiltrates, adventitial fibrosis, but not pulmonary occlusive venopathy were frequently detected. Platelet-derived growth factor signalling pathways were activated in pulmonary vessels of Fra-2 transgenic compared with wild-type mice. Since treatment with nilotinib strongly prevented the development of proliferative vasculopathy and lung fibrosis, the model proved to be sensitive to treatment.

CONCLUSIONS:

This study suggests that Fra-2 transgenic mice as an animal model of systemic sclerosis-associated pulmonary arterial hypertension display main characteristic features of the human disease. It therefore allows studying pathophysiological aspects and might serve as a preclinical model for interventional proof-of-concept studies.

• Authors: Britta Maurer, Nicole Reich, Astrid Juengel, Jörg Kriegsmann, Renate E Gay, Georg Schett, Beat A Michel, Steffen Gay, Jörg H W Distler, Oliver Distler
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 71 Issue 8 Pg. 1382-7 (Aug 2012) ISSN: 1468-2060 [Electronic] England
• PMID: 22523431 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Enzyme Inhibitors
• Fos-Related Antigen-2
• Fosl2 protein, mouse
• Pyrimidines
• Protein-Tyrosine Kinases
• nilotinib

Topics

• Animals
• Disease Models, Animal
• Enzyme Inhibitors (pharmacology)
• Fos-Related Antigen-2 (genetics, metabolism)
• Hypertension, Pulmonary (etiology, metabolism, pathology)
• Lung (metabolism, pathology)
• Lung Diseases, Interstitial (complications, drug therapy, pathology)
• Mice
• Mice, Inbred C57BL
• Mice, Transgenic
• Peripheral Vascular Diseases (drug therapy, etiology, pathology)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pulmonary Artery (drug effects, pathology)
• Pulmonary Circulation (drug effects)
• Pulmonary Fibrosis (drug therapy, etiology, pathology)
• Pyrimidines (pharmacology)
• Scleroderma, Systemic (complications, metabolism, pathology)